The switch to biosimilar rituximab at UCH: 12 months on

The switch to biosimilar rituximab at UCH: 12 months on

VJOncology

1 year
562 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the 2018 British Oncology Pharmacy Association (BOPA) Annual Symposium, Simon Cheesman, MRPharmS, of University College London, London, UK, presented the experiences at University College Hospital London of making the switch to biosimilar rituximab for the treatment of selected patients receiving treatment for follicular lymphoma. One year on, we are joined by Mr Cheesman at the 2018 BOPA Annual Symposium in Birmingham, UK, to hear how this switch has impacted patients responses and treatment costs over the past 12 months. Content on www.vjoncology.com and www.vjhemonc.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd
Up Next Autoplay
BOPA18__VJO_Rachel Elliott_01
BOPA18__VJO_Rachel Elliott_01
Category: Acute Lymphoblastic Leukemia
0 Views
VJOncology 1 year
New models for patient care: advanced pharmacy practitioners
New models for patient care: advanced pharmacy practitioners
Category: General
820 Views
VJOncology 1 year
Patient symptom and experience trackers
Patient symptom and experience trackers
Category: General
587 Views
VJOncology 1 year
Update from the Scottish Cancer Medicines Outcome Programme
Update from the Scottish Cancer Medicines Outcome Programme
Category: General
581 Views
VJOncology 1 year
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
Category: General
368 Views
VJOncology 1 year
Visibility of Oncology Pharmacists to patients
Visibility of Oncology Pharmacists to patients
Category: Other
263 Views
VJOncology 1 year
Smart app to allow patients to manage their side effects independently
Smart app to allow patients to manage their side effects independently
Category: Breast Cancer
80 Views
VJOncology 1 year
cancer-druginteractions.org: a comprehensive tool for HCPs
cancer-druginteractions.org: a comprehensive tool for HCPs
Category: Other
39 Views
VJOncology 1 year
The emergence of mixed speciality oncology
The emergence of mixed speciality oncology
Category: Other
67 Views
VJOncology 1 year